fosmidomycin has been researched along with Parasitemia in 3 studies
fosmidomycin: from Streptomyces lavendulae; RN given refers to parent cpd; structure in second source
fosmidomycin : Propylphosphonic acid in which one of the hydrogens at position 3 is substituted by a formyl(hydroxy)amino group. An antibiotic obtained from Streptomyces lavendulae, it specifically inhibits DXP reductoisomerase (EC 1.1.1.267), a key enzyme in the non-mevalonate pathway of isoprenoid biosynthesis.
Parasitemia: The presence of parasites (especially malarial parasites) in the blood. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fosmidomycin plus clindamycin was shown to be efficacious in the treatment of uncomplicated Plasmodium falciparum malaria in a small cohort of pediatric patients aged 7 to 14 years, but more data, including data on younger children with less antiparasitic immunity, are needed to determine the potential value of this new antimalarial combination." | 9.12 | Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria. ( Adegnika, AA; Borrmann, S; Hutchinson, D; Impouma, B; Issifou, S; Jomaa, H; Kremsner, PG; Kun, JF; Lundgren, I; Matsiegui, PB; Oyakhirome, S; Wiesner, J, 2006) |
| "Fosmidomycin-clindamycin is a promising novel treatment option for malaria." | 6.71 | Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria. ( Adegnika, AA; Borrmann, S; Esser, G; Issifou, S; Jomaa, H; Kremsner, PG; Kun, JF; Matsiegui, PB; Mawili-Mboumba, DP; Missinou, MA; Oyakhirome, S; Ramharter, M, 2004) |
| "Fosmidomycin plus clindamycin was shown to be efficacious in the treatment of uncomplicated Plasmodium falciparum malaria in a small cohort of pediatric patients aged 7 to 14 years, but more data, including data on younger children with less antiparasitic immunity, are needed to determine the potential value of this new antimalarial combination." | 5.12 | Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria. ( Adegnika, AA; Borrmann, S; Hutchinson, D; Impouma, B; Issifou, S; Jomaa, H; Kremsner, PG; Kun, JF; Lundgren, I; Matsiegui, PB; Oyakhirome, S; Wiesner, J, 2006) |
| " Blood samples were taken for pharmacokinetic investigations of clindamycin and/or fosmidomycin and 24-hour urine samples were collected during dosing period." | 2.73 | Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria. ( Chauemung, A; Hutchinson, D; Karbwang, J; Na-Bangchang, K; Ruengweerayut, R, 2007) |
| "Fosmidomycin-clindamycin is a promising novel treatment option for malaria." | 2.71 | Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria. ( Adegnika, AA; Borrmann, S; Esser, G; Issifou, S; Jomaa, H; Kremsner, PG; Kun, JF; Matsiegui, PB; Mawili-Mboumba, DP; Missinou, MA; Oyakhirome, S; Ramharter, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borrmann, S | 2 |
| Issifou, S | 2 |
| Esser, G | 1 |
| Adegnika, AA | 2 |
| Ramharter, M | 1 |
| Matsiegui, PB | 2 |
| Oyakhirome, S | 2 |
| Mawili-Mboumba, DP | 1 |
| Missinou, MA | 1 |
| Kun, JF | 2 |
| Jomaa, H | 2 |
| Kremsner, PG | 2 |
| Lundgren, I | 1 |
| Impouma, B | 1 |
| Hutchinson, D | 2 |
| Wiesner, J | 1 |
| Na-Bangchang, K | 1 |
| Ruengweerayut, R | 1 |
| Karbwang, J | 1 |
| Chauemung, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparative Assessment of the Efficacy of Fosmidomycin-Clindamycin Versus Sulfadoxine-Pyrimethamine for the Treatment of Children With Uncomplicated Plasmodium Falciparum Malaria[NCT00214643] | Phase 3 | 160 participants | Interventional | 2005-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for fosmidomycin and Parasitemia
| Article | Year |
|---|---|
Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria.
Topics: Administration, Oral; Adolescent; Animals; Antimalarials; Blood; Child; Clindamycin; Drug Therapy, C | 2004 |
Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria.
Topics: Administration, Oral; Adolescent; Animals; Antimalarials; Blood; Child; Clindamycin; Drug Therapy, C | 2006 |
Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria.
Topics: Adolescent; Adult; Antimalarials; Clindamycin; Drug Resistance, Multiple; Drug Therapy, Combination; | 2007 |